Executive SummaryMarch 30 merger agreement has been terminated, SciMed announced, noting that the decision "was based on the fact that certain conditions relating to patents would not be satisfied." In March, an Eli Lilly subsidiary sued SciMed for patent infringement resulting from the introduction of a coronary angioplasty catheter. Company added tht the two firms "have begun discussion about the possibility of another type of relationship between them." The stock swap merger was valued at $88 mil.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.